论文部分内容阅读
目的:分析恩替卡韦治疗代偿期乙肝肝硬化的近远期疗效与安全性,观察病人甲状腺激素水平的变化.方法:以40例代偿期乙肝肝硬化病人作为研究对象,都接受恩替卡韦治疗.统计HBV-DNA转阴情况、用药后反应、甲状腺激素变化.结果:用药12周和24周后,HBV-DNA转阴率分别是57.50％和80.00％,4例(10.00％)出现轻微的恶心、头晕感,疗程结束后TSH水平降低,其余甲状腺激素水平升高,,HBV-DNA转阴者TSH水平更高,其余指标数据更低(P＜0.05).结论:恩替卡韦应用在代偿期乙肝肝硬化疾病治疗中近远期疗效与药物安全性都较好,能够优化甲状腺激素水平.","Objective To analyze the short-and long-term efficacy and safety of entecavir in the treatment of compensatory hepatitis B cirrhosis and to observe the changes of thyroid hormones in patients. Methods 40 patients with compensatory hepatitis B cirrhosis were treated with entecavir. The changes of HBV-DNA negative reaction and thyroid hormone were analyzed. Results After 12 weeks and 24 weeks of treatment, the negative rate of HBV-DNA was 57.50％ and 80.004 cases, respectively. There was slight nausea and dizziness. The level of TSH decreased after the treatment, and the level of TSH was higher in the patients whose thyroid hormone level was elevated and HBV-DNA tued negative. The other index data are lower than 0.05. Conclusion Entecavir is effective and safe in the treatment of compensatory hepatitis B cirrhosis, and it can optimize thyroid hormone level.